International Journal of Health Care Finance and Economics

, Volume 7, Issue 2, pp 149–169

The economics of end-stage renal disease care in Canada: incentives and impact on delivery of care

Authors

    • Department of MedicineUniversity of Calgary
    • Department of Community Health SciencesUniversity of Calgary
    • Institute of Health Economics
  • David C. Mendelssohn
    • Humber River Regional HospitalUniversity of Toronto
  • Kenneth J. Taub
    • Department of MedicineUniversity of Calgary
Article

DOI: 10.1007/s10754-007-9022-y

Cite this article as:
Manns, B.J., Mendelssohn, D.C. & Taub, K.J. Int J Health Care Finance Econ (2007) 7: 149. doi:10.1007/s10754-007-9022-y

Abstract

Examining international differences in health outcomes for end-stage renal disease (ESRD) patients requires an understanding of ESRD funding structures. In Canada, funding for all aspects of dialysis and transplant care, with the exception of drugs (for which supplementary insurance can be purchased), is provided for all citizens. Although ESRD programs across Canada’s 10 provinces differ in funding structure, they share important economic characteristics, including being publicly funded and universal, and providing most facets of ESRD care for free. This paper explains how ESRD care fits into the Canadian health care system, describes the epidemiology of ESRD in Canada, and offers economic explanations for international discrepancies.

Keywords

End-stage renal diseaseDialysisHealth care financingMedical costsReimbursementCanada

JEL Classification

I10I11I12I18

Copyright information

© Springer Science+Business Media, LLC 2007